Immunoassay Market Size, Share, Regional Growth, 2026-2034

Market OverviewAccording to fortune business insights, The global immunoassay market size was valued at USD 37.19 billion in 2025. The market is projected to grow from USD 39.48 billion in 2026 to USD 63.72 billion by 2034, exhibiting a CAGR of 6.17% during the forecast period. North America dominated the immunoassay market with a market share of approximately 36% in 2025.

The analysis shows that top companies are investing more in immunoassay technologies because of the rising demand for early and accurate disease diagnosis. For example, healthcare systems increasingly prioritize preventive screening and early intervention, boosting diagnostic testing volumes for infectious diseases, cancer, and cardiovascular disorders. This trend indicates a strong demand for high-throughput, reliable, and cost-effective diagnostic solutions worldwide.

Major Players Profiled in the Market Report:

• F. Hoffmann-La Roche Ltd (Basel, Switzerland)

• Siemens Healthcare Private Limited (Erlangen, Germany)

• bioMérieux SA (Marcy-l'Étoile, France)

• Ortho Clinical Diagnostics (Raritan, U.S.)

• Sysmex Corporation (Kobe, Japan)

• Merck KGaA (Darmstadt, Germany)

• Agilent Technologies, Inc. (California, U.S.)

• DiaSorin S.p.A (Saluggia, Italy)

• Beckman Coulter Inc. (California, U.S.)

SegmentsHigh Recurring Demand to Drive Consumables Segment ExpansionBased on product, the market is divided into instruments and consumables. The consumables segment holds the largest market share, representing approximately 62% of the market, owing to the recurring need for reagents, assay kits, and calibrators for every test performed, which creates a stable and continuous revenue stream.

Superior Sensitivity and Automation to Propel Chemiluminescence Segment GrowthBy technology, the market is categorized into chemiluminescence immunoassay, ELISA, fluoroimmunoassay, radioimmunoassay, and others. The chemiluminescence immunoassay segment is leading the market as it offers superior sensitivity, a wide dynamic range, and is well-suited for fully automated, high-throughput platforms, making it the preferred format for modern diagnostics.

High Prevalence of Heart Disease to Propel Cardiology Segment GrowthBased on application, the market is segmented into cardiology, oncology, autoimmune diseases, and infectious diseases. The cardiology segment holds the largest market share owing to the high global prevalence of cardiovascular disorders and the increasing reliance on advanced diagnostic biomarkers for early detection, risk assessment, and patient management.

Intensive Use in Drug Discovery to Drive Biotech & Pharma Segment DominanceBased on end-user, the market is split into biotechnology and pharmaceutical industries, clinical diagnostic laboratories, and academic and research institutes. The biotechnology and pharmaceutical industries segment leads market growth owing to the extensive use of immunoassays throughout the drug discovery, development, and clinical trial processes for biomarker validation and efficacy monitoring.

Geographically, the market is studied across North America, Europe, Asia Pacific, and the Rest of the World.

Report CoverageThe report offers:

• Major growth drivers, restraining factors, opportunities, and potential challenges for the market.

• Comprehensive insights into regional developments.

• List of major industry players.

• Key strategies adopted by the market players.

• The latest industry developments include product launches, partnerships, mergers, and acquisitions.

Source: https://www.fortunebusinessinsights.com/immunoassay-market-104464

Drivers & RestraintsRising Demand for Early Disease Diagnosis to Propel Market GrowthThe rapid growth in demand for early, accurate, and reliable disease diagnosis has raised the demand for immunoassays, which are essential for detecting biomarkers in infectious diseases, cancer, and chronic conditions. This focus on preventive screening and early intervention is boosting diagnostic testing volumes and driving immunoassay market growth.

However, the high capital cost of advanced immunoassay instruments and automated systems may hamper market growth. Small and mid-sized laboratories in cost-sensitive regions may face budget constraints, slowing the adoption of high-end platforms despite their benefits.

Regional InsightsHighly Developed Healthcare Infrastructure in the U.S. Propels Market Growth in North AmericaNorth America holds the dominant immunoassay market share and is projected to experience steady growth during the forecast period. The region’s growth is attributed to its highly developed healthcare infrastructure, widespread adoption of automated technologies, high testing volumes, and strong R&D activity in biomarker discovery.

Asia Pacific is one of the fastest-growing regions in the market. The growth is attributed to rapid government investment in healthcare infrastructure, modernization of laboratories, and the rising prevalence of infectious and chronic diseases in developing nations, including China and India.

Immunoassay Market Future Growth:The immunoassay market is experiencing robust growth, fueled by rising demand for early disease diagnosis, the growing trend of personalized medicine, and a strong shift toward automated, high-sensitivity platforms. Today's laboratories are increasingly drawn to chemiluminescence and multiplex assays—favoring options that improve accuracy, enhance throughput, and allow for simultaneous detection of multiple biomarkers. Additionally, there's a growing interest in point-of-care immunoassays for rapid, decentralized diagnostics. The rapid expansion of clinical laboratories in emerging markets is also a key growth driver. While North America continues to dominate due to high testing volumes, the Asia-Pacific region is seeing a surge in demand, driven by healthcare infrastructure development.

Competitive LandscapeGrowing Adoption of Automation and Multiplexing Strategies to Propel Market GrowthThe market features prominent players like F. Hoffmann-La Roche Ltd, Siemens Healthcare, and others. These leading companies are accelerating growth through strategic initiatives such as launching high-throughput automated analyzers, expanding multiplex biomarker testing panels, developing ultra-sensitive assays, and forming collaborations for companion diagnostics. Their proactive approach to innovation and improving laboratory efficiency continues to fuel the market’s momentum.

Key Industry Development

• February 2025: F. Hoffmann-La Roche Ltd announced the launch of its next-generation high-throughput automated immunoassay analyzer, designed to enhance laboratory efficiency and diagnostic accuracy for large-scale testing.

• October 2024: Siemens Healthcare entered into a strategic collaboration with a leading oncology firm to develop and commercialize a new companion diagnostic test using its advanced chemiluminescence immunoassay platform.